Physician profile
Margo Weishar
NPI 1295827442
$3,093.08
in general payments reported to CMS, 2019-2025
17 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,124 · 2020: $47.03 · 2022: $107 · 2023: $123 · 2024: $355 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,238.83 | 2019 | |
| Galderma Laboratories, L.P. | $659.25 | 2019-2022 | |
| Allergan, INC. | $329.45 | 2019-2022 | |
| Genzyme Corporation | $199.81 | 2023-2025 | |
| Revance Therapeutics, INC. | $142.50 | 2024-2025 | Daxxify |
| Amgen INC. | $106.99 | 2022-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $102.24 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $56.90 | 2024 | Olumiant, Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $49.73 | 2024 | Sotyktu |
| Botanix Sb INC | $44.66 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $35.72 | 2024-2025 | Zoryve |
| Pfizer INC. | $27.22 | 2024 | |
| Janssen Biotech, INC. | $25.95 | 2025 | Tremfya |
| Organon LLC | $23.90 | 2025 | Vtama |
| Incyte Corporation | $18.61 | 2025 | Opzelura |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $17.23 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margo Weishar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.